Revolution Medicines said its once-daily oral daraxonrasib produced a statistically and clinically meaningful overall survival benefit in its Phase III RASolute 302 trial in metastatic pancreatic ductal adenocarcinoma (PDAC). In the intent-to-treat population, daraxonrasib reached a median OS of 13.2 months versus 6.7 months with standard-of-care chemotherapy, with a hazard ratio of 0.40. The company framed the dataset as potentially practice-changing for patients with RAS-addicted tumors, with plans to move quickly toward global regulatory submissions. Investors responded immediately, with Revolution shares climbing sharply after the announcement. For biotech stakeholders, the update underscores both the durability challenge that has historically limited KRAS-directed approaches and the growing momentum behind second-generation KRAS programs designed to broaden response durability across mutation-defined populations.